Argenx
ARGX
$589.15
Share price
-0.73%
Change (1 day)
48.28%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Revenue for Argenx (ARGX)
Revenue in 2024 (TTM): $1.85 Billion USD
According to Argenx
's latest financial reports the company's current revenue (TTM 
) is $1.85 Billion USD. In 2023 the company made a revenue of $1.22 Billion USD an increase over the revenue in the year 2022 that were of $0.41 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Argenx from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | $1.85 B | 51.57% |
| 2023 | $1.22 B | 198.56% |
| 2022 | $0.41 B | |
| 2019 | $87.64 M | 200.86% |
| 2018 | $29.13 M | -42.03% |
| 2017 | $50.25 M | 193.93% |
| 2016 | $17.09 M | 105.69% |
| 2015 | $8.31 M | 43.78% |
| 2014 | $5.78 M | 16.68% |
| 2013 | $4.95 M |